Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow

K. J. Selvaggi, J. W. Wilson, L. E. Mills, G. G. Cornwell, D. Hurd, W. Dodge, R. Gingrich, S. E. Martin, R. McMillan, W. Miller, E. D. Ball

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We have conducted a 9-year multicenter trial of autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML). Remission BM was purged in vitro using monoclonal antibodies (MoAbs; PM-81, AML-2-23) and complement targeting myeloid differentiation antigens (CD15, CD14). In 1988, the preparative regimen changed from 60 mg/kg/d cyclophosphamide x 2 and fractionated total body irradiation (TBI) total dose, 1,200 cGy (Cy/fTBI), to 4 mg/kg/d busulfan x 4 and 60 mg/kg/d Cy x 2 (Bu/Cy2). Recent analysis (October 1, 1993) shows that the Bu/Cy2 regimen along with the same MoAb purging method yields an improved outcome. Seven first complete-remission (CR) (CR1), 45 second- or third-CR (CR2/3), and 11 first-relapse (R1) patients were treated with chemotherapy and TBI or chemotherapy alone followed by ABMT with MoAb-purged BM. Median age at ABMT for those patients in CR 2/3 and R1 patients was 36 years. Twenty-nine CR 2/3 and R1 patients were conditioned with Cy/fTBI, and 27 CR2/3 and R1 patients were conditioned with Bu/CY. Using the Kaplan-Meier method, the CY/fTBI, CR2/3, and R1 patients have a 3-year disease-free survival (DFS) of 21%. On the other hand, the Bu/Cy2, CR2/3, and R1 patients have a 3-year DFS at 48%. Nineteen CR2/3 and R1 patients relapsed post-ABMT. On analysis by conditioning regimen, those treated with Cy/fTBI have a 3-year relapse rate (RR) of 58%, whereas the patients conditioned with Bu/Cy2 have a 39% 3-year RR. Long-term DFS can be achieved in about 50% of patients with advanced remissions and relapsed AML using Bu/Cy2 with MoAb-purged BM.

Original languageEnglish (US)
Pages (from-to)1698-1705
Number of pages8
JournalBlood
Volume83
Issue number6
StatePublished - Mar 15 1994

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Acute Myeloid Leukemia
Bone
Bone Marrow
Monoclonal Antibodies
Chemotherapy
Irradiation
Purging
Busulfan
Differentiation Antigens
Disease-Free Survival
Cyclophosphamide
Whole-Body Irradiation
Dosimetry
Recurrence
Complement C2
Drug Therapy
Multicenter Studies

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Selvaggi, K. J., Wilson, J. W., Mills, L. E., Cornwell, G. G., Hurd, D., Dodge, W., ... Ball, E. D. (1994). Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood, 83(6), 1698-1705.
Selvaggi, K. J. ; Wilson, J. W. ; Mills, L. E. ; Cornwell, G. G. ; Hurd, D. ; Dodge, W. ; Gingrich, R. ; Martin, S. E. ; McMillan, R. ; Miller, W. ; Ball, E. D. / Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. In: Blood. 1994 ; Vol. 83, No. 6. pp. 1698-1705.
@article{fe9e3ed6f5be48189d6cb45b4d4c410d,
title = "Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow",
abstract = "We have conducted a 9-year multicenter trial of autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML). Remission BM was purged in vitro using monoclonal antibodies (MoAbs; PM-81, AML-2-23) and complement targeting myeloid differentiation antigens (CD15, CD14). In 1988, the preparative regimen changed from 60 mg/kg/d cyclophosphamide x 2 and fractionated total body irradiation (TBI) total dose, 1,200 cGy (Cy/fTBI), to 4 mg/kg/d busulfan x 4 and 60 mg/kg/d Cy x 2 (Bu/Cy2). Recent analysis (October 1, 1993) shows that the Bu/Cy2 regimen along with the same MoAb purging method yields an improved outcome. Seven first complete-remission (CR) (CR1), 45 second- or third-CR (CR2/3), and 11 first-relapse (R1) patients were treated with chemotherapy and TBI or chemotherapy alone followed by ABMT with MoAb-purged BM. Median age at ABMT for those patients in CR 2/3 and R1 patients was 36 years. Twenty-nine CR 2/3 and R1 patients were conditioned with Cy/fTBI, and 27 CR2/3 and R1 patients were conditioned with Bu/CY. Using the Kaplan-Meier method, the CY/fTBI, CR2/3, and R1 patients have a 3-year disease-free survival (DFS) of 21{\%}. On the other hand, the Bu/Cy2, CR2/3, and R1 patients have a 3-year DFS at 48{\%}. Nineteen CR2/3 and R1 patients relapsed post-ABMT. On analysis by conditioning regimen, those treated with Cy/fTBI have a 3-year relapse rate (RR) of 58{\%}, whereas the patients conditioned with Bu/Cy2 have a 39{\%} 3-year RR. Long-term DFS can be achieved in about 50{\%} of patients with advanced remissions and relapsed AML using Bu/Cy2 with MoAb-purged BM.",
author = "Selvaggi, {K. J.} and Wilson, {J. W.} and Mills, {L. E.} and Cornwell, {G. G.} and D. Hurd and W. Dodge and R. Gingrich and Martin, {S. E.} and R. McMillan and W. Miller and Ball, {E. D.}",
year = "1994",
month = "3",
day = "15",
language = "English (US)",
volume = "83",
pages = "1698--1705",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

Selvaggi, KJ, Wilson, JW, Mills, LE, Cornwell, GG, Hurd, D, Dodge, W, Gingrich, R, Martin, SE, McMillan, R, Miller, W & Ball, ED 1994, 'Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow', Blood, vol. 83, no. 6, pp. 1698-1705.

Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. / Selvaggi, K. J.; Wilson, J. W.; Mills, L. E.; Cornwell, G. G.; Hurd, D.; Dodge, W.; Gingrich, R.; Martin, S. E.; McMillan, R.; Miller, W.; Ball, E. D.

In: Blood, Vol. 83, No. 6, 15.03.1994, p. 1698-1705.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow

AU - Selvaggi, K. J.

AU - Wilson, J. W.

AU - Mills, L. E.

AU - Cornwell, G. G.

AU - Hurd, D.

AU - Dodge, W.

AU - Gingrich, R.

AU - Martin, S. E.

AU - McMillan, R.

AU - Miller, W.

AU - Ball, E. D.

PY - 1994/3/15

Y1 - 1994/3/15

N2 - We have conducted a 9-year multicenter trial of autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML). Remission BM was purged in vitro using monoclonal antibodies (MoAbs; PM-81, AML-2-23) and complement targeting myeloid differentiation antigens (CD15, CD14). In 1988, the preparative regimen changed from 60 mg/kg/d cyclophosphamide x 2 and fractionated total body irradiation (TBI) total dose, 1,200 cGy (Cy/fTBI), to 4 mg/kg/d busulfan x 4 and 60 mg/kg/d Cy x 2 (Bu/Cy2). Recent analysis (October 1, 1993) shows that the Bu/Cy2 regimen along with the same MoAb purging method yields an improved outcome. Seven first complete-remission (CR) (CR1), 45 second- or third-CR (CR2/3), and 11 first-relapse (R1) patients were treated with chemotherapy and TBI or chemotherapy alone followed by ABMT with MoAb-purged BM. Median age at ABMT for those patients in CR 2/3 and R1 patients was 36 years. Twenty-nine CR 2/3 and R1 patients were conditioned with Cy/fTBI, and 27 CR2/3 and R1 patients were conditioned with Bu/CY. Using the Kaplan-Meier method, the CY/fTBI, CR2/3, and R1 patients have a 3-year disease-free survival (DFS) of 21%. On the other hand, the Bu/Cy2, CR2/3, and R1 patients have a 3-year DFS at 48%. Nineteen CR2/3 and R1 patients relapsed post-ABMT. On analysis by conditioning regimen, those treated with Cy/fTBI have a 3-year relapse rate (RR) of 58%, whereas the patients conditioned with Bu/Cy2 have a 39% 3-year RR. Long-term DFS can be achieved in about 50% of patients with advanced remissions and relapsed AML using Bu/Cy2 with MoAb-purged BM.

AB - We have conducted a 9-year multicenter trial of autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML). Remission BM was purged in vitro using monoclonal antibodies (MoAbs; PM-81, AML-2-23) and complement targeting myeloid differentiation antigens (CD15, CD14). In 1988, the preparative regimen changed from 60 mg/kg/d cyclophosphamide x 2 and fractionated total body irradiation (TBI) total dose, 1,200 cGy (Cy/fTBI), to 4 mg/kg/d busulfan x 4 and 60 mg/kg/d Cy x 2 (Bu/Cy2). Recent analysis (October 1, 1993) shows that the Bu/Cy2 regimen along with the same MoAb purging method yields an improved outcome. Seven first complete-remission (CR) (CR1), 45 second- or third-CR (CR2/3), and 11 first-relapse (R1) patients were treated with chemotherapy and TBI or chemotherapy alone followed by ABMT with MoAb-purged BM. Median age at ABMT for those patients in CR 2/3 and R1 patients was 36 years. Twenty-nine CR 2/3 and R1 patients were conditioned with Cy/fTBI, and 27 CR2/3 and R1 patients were conditioned with Bu/CY. Using the Kaplan-Meier method, the CY/fTBI, CR2/3, and R1 patients have a 3-year disease-free survival (DFS) of 21%. On the other hand, the Bu/Cy2, CR2/3, and R1 patients have a 3-year DFS at 48%. Nineteen CR2/3 and R1 patients relapsed post-ABMT. On analysis by conditioning regimen, those treated with Cy/fTBI have a 3-year relapse rate (RR) of 58%, whereas the patients conditioned with Bu/Cy2 have a 39% 3-year RR. Long-term DFS can be achieved in about 50% of patients with advanced remissions and relapsed AML using Bu/Cy2 with MoAb-purged BM.

UR - http://www.scopus.com/inward/record.url?scp=0028274055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028274055&partnerID=8YFLogxK

M3 - Article

C2 - 8123862

AN - SCOPUS:0028274055

VL - 83

SP - 1698

EP - 1705

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -